Search results
Showing 1 to 15 of 50 results for barrett's
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.
All NICE products on gastro-oesophageal reflux, including barrett's oesophagus. Includes any guidance, advice and quality standards.
In development Reference number: GID-HTE10070 Expected publication date: TBC
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
Evidence-based recommendations on photodynamic therapy for Barrett's oesophagus. This involves using a light-activated drug (called a photosensitising agent) with a laser to destroy the abnormal cells and to promote the growth of healthy cells.
View recommendations for HTG223Show all sections
Sections for HTG223
Epithelial radiofrequency ablation for Barrett's oesophagus (HTG219)
Evidence-based recommendations on epithelial radiofrequency ablation for Barrett's oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy cells.
View recommendations for HTG219Show all sections
Sections for HTG219
Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.
Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)
This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS96Show all sections
Sections for QS96
- Quality statements
- Quality statement 1: Advice to support self-management
- Quality statement 2: Urgent endoscopy
- Quality statement 3: Testing conditions for Helicobacter pylori
- Quality statement 4: Discussion about referral for non-urgent endoscopy
- Quality statement 5: Referral to a specialist service
- Update information
- About this quality standard
Cytosponge for detecting abnormal cells in the oesophagus (MIB240)
NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .
characteristics, risk factors and predictors that indicate endoscopy for excluding Barrett's oesophagus:- In people who experience...
NG231/04A Question Endoscopic treatments: For adults with Barrett's oesophagus with dysplasia, what is the effectiveness of different...
encourages further research into endoscopic radiofrequency ablation for Barrett's oesophagus with no dysplasia. Studies should define...
endoscopic follow-up for patients who have received endoscopic treatment for Barrett's oesophagus with dysplasia? Any explanatory...